These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28095380)

  • 21. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapeutic approaches in polycythemia vera.
    Foucar CE; Stein BL
    Clin Adv Hematol Oncol; 2018 Nov; 16(11):750-757. PubMed ID: 30543590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
    Vaddi K; Verstovsek S; Kiladjian JJ
    Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
    Parasuraman SV; Shi N; Paranagama DC; Bonafede M
    J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib for the treatment of patients with polycythemia vera.
    Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
    Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
    Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
    Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of polycythemia vera: A survey of treatment patterns in Italy.
    Palumbo GA; Breccia M; Baratè C; Bonifacio M; Elli EM; Iurlo A; Pugliese N; Rossi E; Guglielmelli P; Palandri F
    Eur J Haematol; 2023 Feb; 110(2):161-167. PubMed ID: 36319575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
    Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
    Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
    Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
    Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T
    Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging drugs for polycythemia vera.
    Tibes R; Mesa RA
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):393-404. PubMed ID: 23968379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycythemia vera: aspects of its current diagnosis and initial treatment.
    Silver RT; Abu-Zeinah G
    Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the treatment of polycythemia vera.
    Duek A; Berla M; Ellis MH
    Leuk Lymphoma; 2022 Aug; 63(8):1801-1809. PubMed ID: 35387553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
    Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
    Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thromboembolic events in polycythemia vera.
    Griesshammer M; Kiladjian JJ; Besses C
    Ann Hematol; 2019 May; 98(5):1071-1082. PubMed ID: 30848334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.